Initiation of immunotherapy with activated natural killer cells and anti-GD2 antibody dinutuximab prior to resection of primary neuroblastoma prolongs survival in mice
Background Immunotherapy with anti-disialoganglioside dinutuximab has improved survival for children with high-risk neuroblastoma (NB) when given after induction chemotherapy and surgery. However, disease recurrence and resistance persist. Dinutuximab efficacy has not been evaluated when initiated b...
Saved in:
| Main Authors: | Jianping Sun, Larry Wang, Michael John Zobel, Abigail K Zamora, Hong-wei Wu, Danny Lascano, Jemily Malvar, Michael A Sheard, Robert C Seeger, Eugene S Kim |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2020-10-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| Online Access: | https://jitc.bmj.com/content/8/2/e001560.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Novel drug - dinutuximab for high-risk neuroblastoma
by: Supriya Kushwah, et al.
Published: (2018-01-01) -
Nivolumab and dinutuximab beta in two patients with refractory neuroblastoma
by: Holger Lode, et al.
Published: (2020-05-01) -
GD2 targeting CAR T cells for neuroblastoma
by: John Anderson, et al.
Published: (2024-12-01) -
Hyperleukocytosis in a neuroblastoma patient after treatment with natural killer T cells expressing a GD2-specific chimeric antigen receptor and IL-15
by: Xin Xu, et al.
Published: (2025-01-01) -
Ketamine Infusion as an Adjunct to Opioid Analgesia in Pediatric Patients with High-Risk Neuroblastoma Undergoing Treatment with Dinutuximab: Adverse Effects and Safety in a Non-ICU Setting
by: Streby KA, et al.
Published: (2025-01-01)